NeOnc (NTHI) draws Roth $20 target after positive Phase 2a glioma data
AI Summary
Roth Capital initiated coverage of NeOnc (NTHI) with a Buy and $20 price target, flagging the company’s Phase 2a topline for NEO100 as the near-term catalyst and noting potential pivotal trials before end-2026 under analyst assumptions. NeOnc reported 6‑month PFS of 48.9% vs a prespecified 20% benchmark and median OS of 26.09 months in recurrent IDH1‑mutant high‑grade glioma, is planning FDA meetings to discuss a registrational pathway, has a second program (NEO212) with CMC feedback and a recommended Phase 2 dose, and recently raised about $15M with insider purchases. Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.
Positives
- Roth Capital initiated coverage with a Buy rating and $20 price target on NTHI
- Phase 2a NEO100 topline: 6‑month PFS 48.9% vs 20% prespecified benchmark and median OS 26.09 months
- Company raised ~ $15M in a September registered direct offering and insiders reported multiple stock purchases
Negatives
- Analyst timeline for pivotal trials and commercial launches are expectations, not FDA commitments
- Registrational path depends on upcoming FDA meetings and future pivotal trial outcomes
- Programs remain development-stage; regulatory and clinical risks could delay or prevent approval
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: date unknown
Dilution status
delayed
Dilution timing
Dilution status: Delayed